All HHS Contracts — August 07, 2026

Merck Sharp & Dohme LLC received a $236.3 million cost-plus-fixed-fee contract from BARDA for biotechnology R&D, with options up to $291.4 million, ensuring cost recovery and a fixed profit margin through 2027.

Merck Sharp & Dohme LLC was awarded a $155.8 million firm-fixed-price contract by HHS BARDA/ASPR for ERVEBO procurement, with a 10-year performance period through 2034, providing multi-year revenue visibility.

The $155.8 million ERVEBO contract uses firm-fixed-price pricing, which exposes Merck to cost overrun risk if production or fulfillment expenses exceed the fixed price, potentially compressing margins.

Merck's $155.8 million firm-fixed-price ERVEBO contract carries medium pricing risk; if manufacturing costs exceed the fixed price, margins could be compressed.

Both contracts are awarded to the same entity, Merck Sharp & Dohme LLC, creating a single-contractor concentration risk within this HHS digest.

The $236.3 million BARDA contract depends on continued biodefense funding; any shift in federal budget priorities or a continuing resolution could delay option exercises.

Exercise of the $55.1 million in options on Merck's $236.3 million BARDA contract would signal continued government confidence and provide additional revenue upside.

Full realization of the $173.6 million base-plus-options value on Merck's ERVEBO contract would add approximately $17.8 million in potential revenue beyond the current obligation.

Both contracts originate from BARDA/ASPR within HHS, reflecting sustained government investment in biodefense and pandemic preparedness, a priority area post-COVID-19.

Both Merck contracts have performance periods extending 7-10 years, providing multi-year revenue visibility and reducing quarterly earnings uncertainty.

{"entity" => "Merck & Co., Inc.", "reason" => "Both contracts are awarded to Merck, making it the sole beneficiary of this HHS digest; option exercises and cost performance are key.", "trigger" => "Option exercise announcements on either contract; quarterly earnings reports detailing contract revenue"}

{"entity" => "BARDA/ASPR budget", "reason" => "Continued funding for biodefense and pandemic preparedness is critical for the durability of these contracts.", "trigger" => "FY2027 budget proposal; NDAA biodefense provisions; CR resolution"}